Research Reports

Key takeaways

Positive Phase 3 results for Revolution Medicines' daraxonrasib triggered a $250 million funding tranche from Royalty Pharma.

Royalty Pharma is now entitled to tiered royalties of 4.55% on daraxonrasib sales up to $2 billion, decreasing to 2.50% and 1.00% on higher sales brackets.

An additional $750 million in synthetic royalty funding is available to Revolution Medicines upon achieving regulatory, commercial, and clinical milestones.

If Revolution Medicines fully draws the remaining $750 million, Royalty Pharma's royalty rate would increase to 7.80% on sales up to $2 billion.

Royalty Pharma is also providing a senior secured term loan of up to $750 million in three tranches, with the first $250 million due after FDA approval.

Full analysis

The disclosure centers on the financial implications of positive clinical trial results for a partnered drug. Royalty Pharma's existing $2 billion funding agreement with Revolution Medicines includes both royalty-based and debt components, with today's announcement triggering a specific $250 million payment. This payment adjusts the royalty structure Royalty Pharma will receive from future sales of daraxonrasib, creating a direct link between clinical success and financial return. The agreement includes substantial additional contingent funding ($750 million in synthetic royalties and $750 million in loans) tied to future regulatory and commercial milestones, primarily FDA approval and sales targets. For investors, this represents a milestone-driven capital deployment into a late-stage asset, with Royalty Pharma's future revenue from this partnership now more clearly defined but still contingent on the drug's regulatory approval and commercial success.

RPRX · Royalty Pharma plc

Summary

Key takeaways

Full analysis